

DEFINITIONS

In this document, unless the context otherwise requires, the following terms shall have the meanings set out below. Certain other terms are explained in the section headed “Glossary of Technical Terms” in this document.

“A Share(s)”	ordinary shares issued by our Company, with a nominal value of RMB1.00 each, which are listed on the Shenzhen Stock Exchange and traded in Renminbi
“Accountants’ Report”	the report of our Company’s reporting accountant, Deloitte Touche Tohmatsu, the text of which is set out in Appendix I to this document
“affiliate(s)”	with respect to any specified person, any other person, directly or indirectly, controlling or controlled by or under direct or indirect common control with such specified person
“AFRC”	the Accounting and Financial Reporting Council of Hong Kong
“Articles” or “Articles of Association”	the articles of association of our Company conditionally adopted on October 16, 2025 with effect from the [REDACTED], a summary of which is set out in Appendix V to this document
“Audit Committee”	the audit committee of the Board
“Board” or “Board of Directors”	the board of Directors of our Company
“business day”	any day (other than a Saturday, Sunday or public holiday in Hong Kong) on which banks in Hong Kong are generally open for normal banking business

[REDACTED]

“China”, “Chinese Mainland” or “the PRC”	the People’s Republic of China, excluding, for the purpose of this document only, except where the context requires otherwise, Hong Kong, Macau and Taiwan
“Companies Ordinance”	the Companies Ordinance (Chapter 622 of the Laws of Hong Kong), as amended, supplemented or otherwise modified from time to time
“Companies (Winding Up and Miscellaneous Provisions) Ordinance”	the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Chapter 32 of the Laws of Hong Kong), as amended, supplemented or otherwise modified from time to time
“Company”, “our Company” or “CSPC Innovation”	CSPC Innovation Pharmaceutical Co., Ltd. (石藥創新製藥股份有限公司), a joint stock company with limited liability established in the PRC on April 5, 2006, the A Shares of which have been listed on the Shenzhen Stock Exchange (stock code: 300765)
“Controlling Shareholder(s)”	has the meaning ascribed to it under the Listing Rules and unless the context otherwise requires, refers to NBP Pharmaceutical, CSPC Ouyi, Robust Sun, Dragon Merit and CSPC Pharmaceutical

DEFINITIONS

“CSPC Ouyi”	CSPC Ouyi Pharmaceutical Co., Ltd. (石藥集團歐意藥業有限公司) a company established in the PRC with limited liability on March 29, 2001 and a wholly-owned subsidiary of CSPC Pharmaceutical and one of the Controlling Shareholders
“CSPC Pharmaceutical”	CSPC Pharmaceutical Group Limited (石藥集團有限公司), a company incorporated in Hong Kong with limited liability on June 16, 1992, the shares of which are listed on the Main Board of the Stock Exchange (Stock Code: 1093) and one of the Controlling Shareholders
“CSPC Pharmaceutical Group”	CSPC Pharmaceutical and its subsidiaries
“CSPC Shengxue”	CSPC Shengxue Glucose Co., Ltd. (石藥集團聖雪葡萄糖有限公司) (formerly known as Hebei Shengxue Glucose Limited Liability Company (河北聖雪葡萄糖有限公司)), a company established in the PRC with limited liability on March 30, 2002 and a wholly-owned subsidiary of our Company
“CSRC”	China Securities Regulatory Commission (中國證券監督管理委員會)
“Director(s)”	the director(s) of our Company
“Dragon Merit”	Dragon Merit Holdings Limited (佳曦控股有限公司), a company incorporated under the laws of Hong Kong on January 26, 2012 and a indirectly wholly owned subsidiary of CSPC Pharmaceutical, and is one of the Controlling Shareholders
“EIT”	the enterprise income tax
“EIT Law”	the PRC Enterprise Income Tax Law (《中華人民共和國企業所得稅法》), as amended, supplemented or otherwise modified from time to time
“ESG”	environmental, social and governance
“Extreme Conditions”	the occurrence of “extreme conditions” as announced by the government of Hong Kong in the case of occurrence of a super typhoon or other natural disasters of a substantial scale that seriously affects the working public’s ability to resume work or bring safety concern for a prolonged period

[REDACTED]

“Frost & Sullivan”	Frost & Sullivan (Beijing) Inc., Shanghai Branch Co., our industry consultant
“Frost & Sullivan Report”	the report prepared by Frost & Sullivan

[REDACTED]

“Greater China Region”	Chinese mainland, Hong Kong, Macau, and Taiwan
------------------------	--

DEFINITIONS

“Group”, “our Group”, “the Group”, “we”, “our” or “us”	our Company and its subsidiaries from time to time or, where the context so requires in respect of the period before our Company became the holding company of our present subsidiaries, such subsidiaries as if they were subsidiaries of our Company at the relevant time
“Guide for New Listing Applicants”	the Guide for New Listing Applicants issued by the Stock Exchange in December 2023, and as amended, supplemented or otherwise modified from time to time
	[REDACTED]
“H Share(s)”	overseas [REDACTED] foreign shares in the share capital of our Company with a nominal value of RMB1.00 each, which are [REDACTED] in Hong Kong dollars and are to be [REDACTED] on the Stock Exchange
“Hebei GWK”	Hebei Zhongnuo GWK Medicines & Health Products Co., Ltd (河北中諾果維康保健品有限公司), a company established in the PRC with limited liability on October 12, 2015 and a wholly-owned subsidiary of our Company
“HK” or “Hong Kong”	the Hong Kong Special Administrative Region of the PRC

[REDACTED]

“HK\$” or “Hong Kong dollar(s)”	Hong Kong dollars, the lawful currency of Hong Kong
“HKAS”	Hong Kong Accounting Standards issued by the Hong Kong Institute of Certified Public Accountants
“HKFRS”	Hong Kong Financial Reporting Standards issued by the Hong Kong Institute of Certified Public Accountants
“HKICPA”	Hong Kong Institute of Certified Public Accountants

[REDACTED]

DEFINITIONS

[REDACTED]

“Hong Kong Takeovers Code” or “Takeover Codes”	the Code on Takeovers and Mergers and Share Buy-backs issued by the SFC, as amended, supplemented or otherwise modified from time to time
---	---

[REDACTED]

“IFRS”	International Financial Reporting Standards, as issued from time to time by the International Accounting Standards Board
--------	--

“Independent Third Party(ies)”	any entity or person who is not a connected person of our Company within the meaning ascribed to it under the Listing Rules
--------------------------------	---

[REDACTED]

DEFINITIONS

[REDACTED]

“Latest Practicable Date” June 10, 2026, being the latest practicable date for ascertaining certain information contained in this document before its publication

[REDACTED]

“Listing Committee” the listing committee of the Stock Exchange

[REDACTED]

“Listing Rules” the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, as amended, supplemented or otherwise modified from time to time

“Main Board” the stock market (excluding the option market) operated by the Stock Exchange which is independent from and operated in parallel with GEM of the Stock Exchange

“Megalith Biopharmaceutical” CSPC Megalith Biopharmaceutical Co., Ltd (石藥集團巨石生物製藥有限公司), a company incorporated in the PRC on April 16, 2019, and a non-wholly owned subsidiary of our Company

“MIIT” the Ministry of Industry and Information Technology of the PRC (中華人民共和國工業和信息化部)

“Ministry of Finance” or “MOF” Ministry of Finance of the PRC (中華人民共和國財政部)

“MOFCOM” Ministry of Commerce of the PRC (中華人民共和國商務部)

“NBP Pharmaceutical” CSPC NBP Pharmaceutical Co., Ltd. (石藥集團恩必普藥業有限公司), a foreign investment enterprise with limited liability established under the laws of the PRC on April 23, 2003, a wholly-owned subsidiary of CSPC Pharmaceutical and one of the Controlling Shareholders

“NDRC” National Development and Reform Commission of the PRC (中華人民共和國國家發展和改革委員會)

“Nomination Committee” the nomination committee of the Board

DEFINITIONS

“NPC of the PRC” National People’s Congress of the PRC (中華人民共和國全國人民代表大會)

[REDACTED]

“Overseas Listing Trial Measures” the Trial Administrative Measures of Overseas Securities Offering and Listing by Domestic Companies (《境內企業境外發行證券和上市管理試行辦法》) promulgated by the CSRC on February 17, 2023, as amended, supplemented or otherwise modified from time to time

“PBOC” the People’s Bank of China (中國人民銀行), the central bank of the PRC

“PCT” The Patent Cooperation Treaty

“PRC Company Law” the Company Law of the PRC (《中華人民共和國公司法》), as amended, modified and/or otherwise supplemented from time to time

“PRC GAAP” generally accepted accounting principles in Chinese Mainland

“PRC Government” or “State” the central government of the PRC, including all political subdivisions (including provincial, municipal and other regional or local government entities) and its organs or, as the context requires, any of them

“PRC Legal Adviser” Hai Run Law Firm, our legal adviser as to PRC laws

“PRC Securities Law” the Securities Law of the PRC (《中華人民共和國證券法》), as amended, supplemented or otherwise modified from time to time

[REDACTED]

DEFINITIONS

[REDACTED]

“province”	a province or, where the context requires, a provincial level autonomous region or municipality, under the direct supervision of the central government of the PRC
“QIBs” or “Qualified Institutional Buyers”	qualified institutional buyers within the meaning of Rule 144A under the U.S. Securities Act
“R&D”	research and development
“Regulation S”	Regulation S under the U.S. Securities Act
“Remuneration and Evaluation Committee”	the remuneration and evaluation committee of the Board
“RMB” or “Renminbi”	Renminbi, the lawful currency of the PRC
“Robust Sun”	Robust Sun Holdings Limited (康日控股有限公司), a company incorporated in the British Virgin Islands on May 23, 2012 and a wholly owned subsidiary of CSPC Pharmaceutical, and is one of the Controlling Shareholders
“Rule 144A”	Rule 144A under the U.S. Securities Act
“SAFE”	State Administration of Foreign Exchange of the PRC (中華人民共和國國家外匯管理局)
“SAIC”	State Administration of Industry and Commerce of the PRC (中華人民共和國國家工商行政管理總局), which has now been merged into the SAMR
“SAMR”	State Administration for Market Regulation of the PRC (中華人民共和國國家市場監督管理總局)
“SAT”	State Administration of Taxation of the PRC (中華人民共和國國家稅務總局)
“SFC”	the Securities and Futures Commission of Hong Kong
“SFO”	Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong), as amended, supplemented or otherwise modified from time to time
“Shanghai-Hong Kong Stock Connect”	a securities trading and clearing links program developed by the Stock Exchange, Shanghai Stock Exchange, HKSCC and China Securities Depository and Clearing Corporation Limited for mutual market access between Hong Kong and Shanghai
“Megalith Shanghai”	CSPC Megalith Biopharmaceutical (Shanghai) Co., Ltd. (石藥巨石生物製藥(上海)有限公司), a company established in the PRC with limited liability on October 10, 2024 and a non-wholly owned subsidiary of our Company
“Shanghai Stock Exchange”	the Shanghai Stock Exchange (上海證券交易所)
“Share(s)”	ordinary share(s) in the share capital of our Company, with a nominal value of RMB1.00 each, comprising our A Shares and upon [REDACTED], our H Shares
“Shareholder(s)”	holder(s) of the Shares

DEFINITIONS

“Shenzhen-Hong Kong Stock Connect”	a securities trading and clearing links program developed by the Hong Kong Stock Exchange, Shenzhen Stock Exchange, HKSCC and China Securities Depository and Clearing Corporation Limited for mutual market access between Hong Kong and Shenzhen
“Shenzhen Stock Exchange” or “SZSE”	the Shenzhen Stock Exchange (深圳證券交易所)
“Shijiazhuang Henglu”	Shijiazhuang Henglu Biotechnology Co., Ltd. (石家莊恆魯生物科技股份有限公司), a company established in the PRC with limited liability on September 20, 2023 and a non-wholly owned subsidiary of our Company
“Sole Sponsor”	the sole sponsor as named in the “Directors and Parties Involved in the [REDACTED]” section of this document
	[REDACTED]
“State Council”	State Council of the People’s Republic of China (中華人民共和國國務院)
“Stock Exchange” or “Hong Kong Stock Exchange”	The Stock Exchange of Hong Kong Limited
“Strategy and ESG Committee”	the strategy and ESG committee of the Board
“Taizhou GWK”	CSPC Taizhou GWK Medicines & Health Products Co., Ltd. (石藥集團泰州果維康保健品有限公司), a company established in the PRC with limited liability on December 22, 2015 and a wholly-owned subsidiary of our Company
“Track Record Period”	the financial years ended December 31, 2023, 2024 and 2025
	[REDACTED]
“US\$”, “USD” or “U.S. dollars”	United States dollars, the lawful currency of the United States
“U.S.” or “United States”	the United States of America, its territories, its possessions and all areas subject to its jurisdiction
“U.S. FDA” or “FDA”	the Food and Drug Administration of the United States
“U.S. Securities Act”	the United States Securities Act of 1933, as amended from time to time, and the rules and regulations promulgated thereunder
“VAT”	value added tax
“Zhongnuo Taizhou”	CSPC Zhongnuo Pharmaceutical (Taizhou) Co., Ltd. (石藥集團中諾藥業(泰州)有限公司), a company established in the PRC with limited liability on August 22, 2011 and a wholly-owned subsidiary of our Company
“%”	per cent

In this document, the terms “associate”, “close associate”, “connected person”, “core connected person”, “connected transaction”, “subsidiary” and “substantial shareholder” shall have the meanings given to such terms in the Listing Rules, unless the context otherwise requires.

The English names of the PRC entities, PRC laws or regulations, and the PRC governmental authorities referred to in this document are translations from their Chinese names and are for identification purposes. If there is any inconsistency, the Chinese names shall prevail.